EXEL
HealthcareExelixis, Inc. · Biotechnology · $13B
What is Exelixis, Inc.?
Exelixis is an oncology-focused biotechnology company dedicated to discovering, developing, and commercializing medicines that treat cancer. Headquartered in Alameda, California, it has built a commercial presence around its cabozantinib-based therapies.
Exelixis generates revenue primarily through sales of CABOMETYX and COMETRIQ, both derived from cabozantinib — a tyrosine kinase inhibitor targeting pathways involved in tumor growth and spread. The company also earns from collaboration and licensing agreements with partners including Ipsen, Takeda, and Roche, while advancing a pipeline of next-generation oncology candidates.
Exelixis was founded in 2000 and is headquartered in Alameda, California.
- CABOMETYX — for advanced renal cell carcinoma
- COMETRIQ — for progressive metastatic medullary thyroid cancer
- COTELLIC — combination therapy for advanced melanoma
- Pipeline candidates including XL092, XB002, and XL102
Is EXEL a Good Stock to Buy?
UQS Score rates EXEL as Good overall, reflecting a balanced profile across its five quality pillars.
Exelixis stands out for its Strong Quality and Risk ratings, suggesting a financially disciplined operation with a manageable risk profile relative to biotech peers. The Valuation pillar is rated Attractive, which may interest investors seeking exposure at a reasonable entry point.
The Moat and Growth pillars both register as Neutral, indicating the company faces competitive pressures and may not yet demonstrate the durable competitive advantages or expansion trajectory of sector leaders.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does EXEL pay dividends?
No — Exelixis, Inc. does not currently pay a dividend.
Exelixis does not currently pay a dividend. As an oncology biotech, the company reinvests available capital into clinical-stage pipeline development and commercial operations — a common approach for companies prioritizing long-term growth over near-term income distribution.
When does EXEL report earnings?
Exelixis reports earnings on a quarterly cadence, consistent with US-listed equities.
The company's commercial portfolio, anchored by CABOMETYX, has driven consistent revenue generation. Collaboration revenues from licensing partners add a secondary income stream that can vary quarter to quarter based on milestone achievements and royalty activity.
For the most recent quarter's results, visit Exelixis's investor relations page directly.
EXEL Price History
+103.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
Frequently Asked Questions
What does Exelixis do?
Exelixis is an oncology biotechnology company that discovers, develops, and commercializes cancer medicines. Its primary marketed products are CABOMETYX and COMETRIQ, both based on cabozantinib, a tyrosine kinase inhibitor. The company also has a pipeline of next-generation oncology candidates and earns revenue through licensing partnerships.
Does EXEL pay dividends?
No, Exelixis does not pay a dividend. The company reinvests capital into its oncology pipeline and commercial operations rather than distributing cash to shareholders. Investors seeking income may want to factor this into their assessment.
When does EXEL report earnings?
Exelixis reports on a standard quarterly schedule. For confirmed dates and the most recent results, check the investor relations section of the Exelixis website.
Is EXEL a good stock to buy?
UQS Score rates EXEL as Good, with particularly Strong Quality and Risk scores and an Attractive Valuation rating. Moat and Growth are Neutral. Whether it fits your portfolio depends on your individual goals — the full pillar breakdown is available to Pro members.
Is EXEL overvalued?
The UQS Valuation pillar for EXEL is rated Attractive, suggesting the stock may be reasonably priced relative to its fundamentals compared to sector peers. For the detailed valuation metrics behind this rating, a Pro account provides the complete view.
What is EXEL's market cap bracket?
Exelixis is classified as a large-cap company, placing it among the more substantial publicly traded biotechnology firms by market value.
Is EXEL a long-term quality investment?
From a quality standpoint, EXEL's Strong Quality and Risk pillar ratings suggest a disciplined, lower-risk operation within the volatile biotech sector. Neutral Moat and Growth scores indicate areas to monitor. Long-term suitability depends on how the pipeline and competitive position evolve.
Who founded Exelixis?
Exelixis was founded in 2000. Founding details are widely available through public company filings and the Exelixis corporate history page.
Unlock Full EXEL Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Moat, Growth, Risk, and Valuation
- ✓Access detailed financial metrics behind each pillar rating
- ✓Compare EXEL side-by-side with oncology and biotech peers
- ✓Track score changes over time with historical UQS data
Pro Analysis
EXEL — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 69.6 | 98.6 | 41.0 | 52.5 | 82.4 | 78.9 | +0.1 |
| May 21, 2026 | 69.5 | 98.6 | 41.0 | 52.5 | 82.4 | 78.2 | +0.4 |
| May 13, 2026 | 69.1 | 98.1 | 41.0 | 52.5 | 82.4 | 76.7 | -0.3 |
| May 11, 2026 | 69.4 | 98.7 | 41.0 | 52.5 | 82.4 | 77.5 | +1.1 |
| May 7, 2026 | 68.3 | 98.6 | 41.0 | 48.0 | 82.4 | 76.4 | -0.7 |
| May 3, 2026 | 69.0 | 98.6 | 41.0 | 48.0 | 82.4 | 81.0 | +0.2 |
| Apr 28, 2026 | 68.8 | 98.6 | 41.0 | 48.0 | 82.4 | 79.9 | -0.1 |
| Apr 25, 2026 | 68.9 | 98.6 | 41.0 | 48.1 | 82.4 | 80.0 | +0.2 |
| Apr 23, 2026 | 68.7 | 98.0 | 41.0 | 48.1 | 82.4 | 79.5 | -0.5 |
| Apr 21, 2026 | 69.2 | 99.1 | 41.0 | 48.1 | 82.4 | 81.2 | +0.2 |
EXEL — Pillar Breakdown
Quality
— 98.6/100 (25%)Exelixis, Inc. demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 52.6/100 (20%)Exelixis, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 82.4/100 (15%)Exelixis, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 77.8/100 (15%)Exelixis, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 41/100 (25%)Exelixis, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for EXEL.
Score Composition
Financial Data
More Stock Analysis
How is the EXEL UQS Score Calculated?
The UQS (Unified Quality Score) for Exelixis, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Exelixis, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Exelixis, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.